Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma

Semin Hematol. 2005 Oct;42(4 Suppl 4):S1-2. doi: 10.1053/j.seminhematol.2005.10.005.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / immunology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytokines / antagonists & inhibitors
  • Cytokines / immunology
  • Dexamethasone / immunology
  • Dexamethasone / therapeutic use
  • Humans
  • Immunologic Factors / immunology
  • Immunologic Factors / therapeutic use*
  • Lenalidomide
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Thalidomide / analogs & derivatives*
  • Thalidomide / immunology
  • Thalidomide / therapeutic use*

Substances

  • Cytokines
  • Immunologic Factors
  • Thalidomide
  • Dexamethasone
  • Lenalidomide